Philips Earnings Call: Growth Builds Amid Tariff Strain

Koninklijke Philips N.V. ((PHG)) has held its Q4 earnings call. Read on for the main highlights of the call.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Philips’ latest earnings call struck a cautiously upbeat tone, with management highlighting accelerating sales, stronger orders and expanding margins across most businesses. Executives balanced this optimism with clear warnings about tariff headwinds, lingering Respironics liabilities and a soft China market, arguing that ongoing productivity gains and pricing actions should keep the 2026 targets within reach.

Strong Q4 Orders and Sales Momentum

Order intake rose 7% in the fourth quarter and 6% for the full year, underscoring renewed demand across key franchises. Comparable sales growth accelerated to 7% in Q4, lifting full‑year growth to 2.3% and supporting a 5% expansion of the order book, which management says improves visibility into 2026 revenue.

Improved Profitability and Margins

Profitability strengthened meaningfully as adjusted EBITDA margin climbed to 15.1% in Q4, 160 basis points higher year on year. For the full year, the adjusted EBITDA margin improved to 12.3%, helped by sales leverage, richer product mix and substantial productivity gains that management expects to build on.

Personal Health Outperformance

Personal Health emerged as a standout, with comparable sales up 14% in Q4 and 8% for the year, backed by premium products like OneBlade, DiamondClean and high‑end shavers. Segment profitability surged, with Q4 adjusted EBITDA margin reaching 23% and full‑year margin 18%, reflecting strong brand positioning and tight commercial execution.

Connected Care Momentum

Connected Care maintained solid growth, posting 7% comparable sales improvement in Q4 and 3% for the full year, driven by rising demand in North American monitoring and informatics. The unit’s Q4 adjusted EBITDA margin increased to 16.5%, while full‑year margin moved into double digits at 10.7%, aided by large strategic partnerships.

Order Strength in Diagnosis & Treatment

Diagnosis & Treatment saw order intake rise 5% for the year, signaling healthy medium‑term demand despite modest sales growth. Image‑Guided Therapy delivered double‑digit Q4 growth, supported by strong uptake of Azurion 7, EPIQ CVx ultrasound and CT 5300, plus a 10‑year deal with Bon Secours Mercy Health covering more than 80 labs.

Innovation Pipeline and Strategic M&A

Management underscored a deep innovation pipeline, including a helium‑free 3T MRI, always‑on spectral CT platform Verida and AI‑enabled LumiGuide 3D navigation. The acquisition of SpectraWAVE, focused on high‑definition intravascular imaging, is expected to bolster the Image‑Guided Therapy portfolio and support future gross‑margin expansion.

Material Productivity and Cost Savings

Philips continued to lean heavily on productivity, delivering €248 million of savings in Q4 and €815 million for the year, taking total savings since 2023 to over €2.5 billion, above the original goal. Building on this, the company announced a new €1.5 billion productivity program for 2026–2028 to help counter tariff pressure and fund investments.

Improved Earnings, Cash and Leverage

Adjusted diluted EPS from continuing operations increased 20% in Q4 to €0.60 and 15% for the year, underpinned by higher margins and disciplined costs. Free cash flow reached €1.2 billion in Q4, year‑end cash stood near €2.8 billion and net debt about €5.3 billion, bringing leverage down to 1.7 times adjusted EBITDA.

Tariffs Creating Ongoing Headwinds

Tariffs have already weighed on margins, though 2025 impact came in better than the earlier €150–200 million estimate after mitigation. However, management warned that fully annualized tariffs in 2026 will still be a €250–300 million net headwind at current levels, putting particular pressure on early‑2026 profitability despite planned offsets.

Respironics Recall and Legal Uncertainty

The legacy Respironics recall continues to cast a shadow through regulatory and legal overhangs, including an FDA warning letter and consent‑decree‑related quality actions. Around €1 billion of cash payments related to U.S. settlements weighed on full‑year cash flow, while an ongoing DOJ investigation remains outside the financial outlook.

Adjusting Items and Other Charges

Adjusting items totaled €179 million in Q4 and €531 million for the year, broadly in line with guidance of roughly 300 basis points of sales. For 2026, Philips expects adjusting items near 200 basis points and other charges of about 120 basis points, including consent decree costs, field actions and acquisition‑related expenses.

China Market Challenges

China remains a weak spot, with subdued hospital activity, slower tender processing and intense competition from centralized procurement weighing on growth. Management now assumes that China sales will be broadly stable rather than a growth driver in 2026, even as Personal Health shows some improvement at the retail sell‑out level.

Diagnosis & Treatment Margin Pressure

While Diagnosis & Treatment posted 4% comparable sales growth in Q4, full‑year sales were flat, reflecting a more challenging backdrop and delayed revenue conversion from orders. Tariffs hit D&T margins, leading to a 30‑basis‑point decline in Q4 adjusted EBITDA margin to 11.8% despite productivity and innovation benefits.

Free Cash Flow Volatility

Fourth‑quarter free cash flow of €1.2 billion was €85 million below the prior year, with 2024 figures supported by a €367 million Respironics insurance receipt. Full‑year free cash flow came in at €512 million after large settlement outflows, highlighting that cash generation remains sensitive to non‑recurring legal and insurance items.

Near‑Term Phasing and Q1 Margin Weakness

Management cautioned that 2026 will start slowly, with first‑quarter sales growth expected at the lower end of the annual range and a slight margin decline. The pattern should resemble Q1 2025 as tariff annualization and seasonal effects temporarily outweigh operating leverage before momentum builds later in the year.

Macro and Policy Uncertainty

Executives also flagged broader macroeconomic and policy risks, including potential new trade measures such as additional metal tariffs. While Philips is pushing regionalization and other mitigation strategies, management acknowledged that these uncertainties introduce both upside and downside risks to the medium‑term outlook.

Forward‑Looking Guidance and 2026 Targets

For 2026, Philips guided to 3.0%–4.5% comparable sales growth and an adjusted EBITDA margin of 12.5%–13.0%, with all quarters within the range but Q1 at the low end. The company expects €1.3–1.5 billion of free cash flow, assumes full tariff annualization and plans to offset much of the pressure through continued operational improvements and a new €1.5 billion productivity program.

Philips’ earnings call painted a picture of a company rebuilding growth and margins while still grappling with legacy and macro headwinds. Strong order intake, improving profitability and a robust innovation pipeline underpin confidence in the 2026 targets, but investors will watch closely how the group navigates tariffs, legal overhangs and a subdued China market over the next year.

Disclaimer & DisclosureReport an Issue